NERV
Minerva NeurosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The constructive case is that Minerva has moved from planning into active Phase 3 execution, has FDA-aligned trial design language in company materials, and retains differentiated positioning in an area with no approved treatment for negative symptoms of schizophrenia [#SEC-8K-2026-03-11] [#SEC-8K-2026-05-05].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.3.
What can break
Dilution and warrant overhang remain relevant even after the October 2025 financing package.
Momentum
86
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $7.00 · Bear $2.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.50
Why
Momentum86 · Δ7d -5.3
Value41 · Δ7d +0.1
Sentiment48 · Δ7d +5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendSoftening
Δ7d
-5.3
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
48
34% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
-
Why this grade
Composite grade B. Momentum 85.6 / Value 41.1 / Sentiment 48.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$208.72M
Beta
-0.24
Shares Out
46.59M
P/E (TTM)
2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.79
Rev YoY
-100.0%
EPS YoY
+476.2%
Gross Margin
-
Op Margin
-
Net Debt
-$17.44M
Current Ratio
17.65
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology